Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 1/2020

01-01-2020 | Review – Cancer Research

Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance

Authors: Masoud Najafi, Bagher Farhood, Keywan Mortezaee, Ebrahim Kharazinejad, Jamal Majidpoor, Reza Ahadi

Published in: Journal of Cancer Research and Clinical Oncology | Issue 1/2020

Login to get access

Abstract

Purpose

Cancer stem cells (CSCs) are highly tumorigenic cell types that reside within specific areas of tumor microenvironment (TME), and are endowed with self-renewal and resistance properties. Here, we aimed to discuss mechanisms involved in hypoxia-derived CSC resistance and targeting for effective cancer therapy.

Results

Preferential localization within hypoxic niches would help CSCs develop adaptive mechanisms, mediated through the modification of responses to various stressors and, as a result, show a more aggressive behavior.

Conclusion

Hypoxia, in fact, serves as a multi-tasking strategy to nurture CSCs with this adaptive capacity, complexing targeted therapies.
Literature
Abyaneh HS, Gupta N, Alshareef A, Gopal K, Lavasanifar A, Lai R (2018) Hypoxia induces the Acquisition of Cancer Stem-like Phenotype via Upregulation and Activation of signal transducer and activator of Transcription-3 (STAT3) in MDA-MB-231, a triple negative breast Cancer cell line. Cancer Microenviron 11(2–3):141–152CrossRef
Agnihotri N, Kumar S, Mehta K (2013) Tissue transglutaminase as a central mediator in inflammation-induced progression of breast cancer. Breast Cancer Res 15(1):202PubMedPubMedCentralCrossRef
Alama A, Orengo AM, Ferrini S, Gangemi R (2012) Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies? Drug Discov Today 17(9–10):435–442PubMedCrossRef
Alipour M, Majidi A, Molaabasi F, Sheikhnejad R, Hosseinkhani S (2018) In vivo tumor gene delivery using novel peptideticles: pH-responsive and ligand targeted core–shell nanoassembly. Int J Cancer 143(8):2017–2028PubMedCrossRef
Anuja K, Chowdhury AR, Saha A, Roy S, Rath AK, Kar M, Banerjee B (2019) Radiation-induced DNA damage response and resistance in colorectal cancer stem-like cells. Int J Radiat Biol 95(6):667–679PubMedCrossRef
Balamurugan K (2016) HIF-1 at the crossroads of hypoxia, inflammation, and cancer. Int J Cancer 138(5):1058–1066CrossRefPubMed
Bao B, Azmi AS, Ali S, Ahmad A, Li Y, Banerjee S, Kong D, Sarkar FH (2012) The biological kinship of hypoxia with CSC and EMT and their relationship with deregulated expression of miRNAs and tumor aggressiveness. Biochimica et Biophysica Acta (BBA)-Rev Cancer 1826(2):272–296CrossRef
Baumann M, Krause M, Hill R (2008) Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 8(7):545PubMedCrossRef
Boccaccio C, Comoglio PM (2006) Invasive growth: a MET-driven genetic programme for cancer and stem cells. Nat Rev Cancer 6(8):637PubMedCrossRef
Bonnin DA, Havrda M, Lee M, Liu H, Zhang Z, Nguyen L, Harrington L, Hassanpour S, Cheng C, Israel M (2018) Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia. Oncogene 37(8):1107CrossRef
Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T (2005) Migrating cancer stem cells—an integrated concept of malignant tumour progression. Nat Rev Cancer 5(9):744PubMedCrossRef
Carnero A, Lleonart M (2016) The hypoxic microenvironment: a determinant of cancer stem cell evolution. BioEssays 38:S65–S74PubMedCrossRef
Chen A, Sceneay J, Gödde N, Kinwel T, Ham S, Thompson EW, Humbert PO, Möller A (2018) Intermittent hypoxia induces a metastatic phenotype in breast cancer. Oncogene 37(31):4214–4225PubMedCrossRef
Chen J, Xu R, Xia J, Huang J, Su B, Wang S (2019) Aspirin inhibits hypoxia-mediated lung cancer cell stemness and exosome function. Pathol Res Pract 215(6):152379PubMedCrossRef
Chouaib S, Noman M, Kosmatopoulos K, Curran M (2017) Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene 36(4):439PubMedCrossRef
Colwell N, Larion M, Giles AJ, Seldomridge AN, Sizdahkhani S, Gilbert MR, Park DM (2017) Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells. Neuro-Oncol 19(7):887–896PubMedPubMedCentralCrossRef
Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 62(12):3387–3394PubMed
Conley SJ, Gheordunescu E, Kakarala P, Newman B, Korkaya H, Heath AN, Clouthier SG, Wicha MS (2012) Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia. Proc Natl Acad Sci 109(8):2784–2789PubMedCrossRefPubMedCentral
Conley SJ, Baker TL, Burnett JP, Theisen RL, Lazarus D, Peters CG, Clouthier SG, Eliasof S, Wicha MS (2015) CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer. Breast Cancer Res Treat 150(3):559–567PubMedCrossRef
Conway JR, Warren SC, Herrmann D, Murphy KJ, Cazet AS, Vennin C, Shearer RF, Killen MJ, Magenau A, Mélénec P (2018) Intravital imaging to monitor therapeutic response in moving hypoxic regions resistant to PI3K pathway targeting in pancreatic cancer. Cell Rep 23(11):3312–3326PubMedPubMedCentralCrossRef
Cressey PB, Eskandari A, Bruno PM, Lu C, Hemann MT, Suntharalingam K (2016) The potent inhibitory effect of a naproxen-appended Cobalt (III)-Cyclam complex on cancer stem cells. ChemBioChem 17(18):1713–1718PubMedCrossRef
Csermely P, Hódsági J, Korcsmáros T, Módos D, Perez-Lopez ÁR, Szalay K, Veres DV, Lenti K, Wu L-Y, Zhang X-S (2015) Cancer stem cells display extremely large evolvability: alternating plastic and rigid networks as a potential mechanism: network models, novel therapeutic target strategies, and the contributions of hypoxia, inflammation and cellular senescence. Semin Cancer Biol 30:42–51PubMedCrossRef
Das B, Pal B, Bhuyan R, Li H, Sarma A, Gayan S, Talukdar J, Sandhya S, Bhuyan S, Gogoi G (2019) MYC regulates the HIF2α stemness pathway via Nanog and Sox2 to maintain self-renewal in cancer stem cells versus non-stem cancer cells. Cancer Res 79(16):4015–4025PubMedCrossRefPubMedCentral
de Jong MC, Jelle J, Grénman R, Wessels LF, Kerkhoven R, te Riele H, van den Brekel MW, Verheij M, Begg AC (2015) Pretreatment microRNA expression impacting on epithelial-to-mesenchymal transition predicts intrinsic radiosensitivity in head and neck cancer cell lines and patients. Clin Cancer Res 21(24):5630–5638PubMedCrossRef
Deshmukh A, Deshpande K, Arfuso F, Newsholme P, Dharmarajan A (2016) Cancer stem cell metabolism: a potential target for cancer therapy. Mol Cancer 15(1):69PubMedPubMedCentralCrossRef
Dong X-F, Liu T-Q, Zhi X-T, Zou J, Zhong J-T, Li T, Mo X-L, Zhou W, Guo W-W, Liu X (2018) COX-2/PGE2 axis regulates HIF2α activity to promote hepatocellular carcinoma hypoxic response and reduce the sensitivity of sorafenib treatment. Clin Cancer Res 24(13):3204–3216PubMedCrossRef
Eckert F, Zwirner K, Boeke S, Thorwarth D, Zips D, Huber SM (2019) Rationale for combining radiotherapy and immune checkpoint inhibition for patients with hypoxic tumors. Front Immunol 10:407PubMedPubMedCentralCrossRef
Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le Q-T, Giaccia AJ (2009) Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 15(1):35–44PubMedPubMedCentralCrossRef
Farhood B, Najafi M, Mortezaee K (2019) CD8+ cytotoxic T lymphocytes in cancer immunotherapy: a review. J Cell Physiol 234(6):8509–8521PubMedCrossRef
Feitelson MA, Arzumanyan A, Kulathinal RJ, Blain SW, Holcombe RF, Mahajna J, Marino M, Martinez-Chantar ML, Nawroth R, Sanchez-Garcia I (2015) Sustained proliferation in cancer: mechanisms and novel therapeutic targets. Semin Cancer Biol 35:S25–S54PubMedPubMedCentralCrossRef
Gaelzer MM, dos Santos MS, Coelho BP, de Quadros AH, Simão F, Usach V, Guma FCR, Setton-Avruj P, Lenz G, Salbego CG (2017) Hypoxic and reoxygenated microenvironment: stemness and differentiation state in glioblastoma. Mol Neurobiol 54(8):6261–6272PubMedCrossRef
Gao H, Teng C, Huang W, Peng J, Wang C (2015) SOX2 Promotes the epithelial to mesenchymal transition of esophageal squamous cells by modulating slug expression through the activation of STAT3/HIF-α Signaling. Int J Mol Sci 16(9):21643–21657PubMedPubMedCentralCrossRef
Ghoshal S, Fuchs BC, Tanabe KK (2016) STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC. Hepatobiliary Surg Nutr 5(3):201PubMedPubMedCentralCrossRef
Giannoni E, Bianchini F, Calorini L, Chiarugi P (2011) Cancer associated fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchymal transition and stemness. Antioxid Redox Signal 14(12):2361–2371PubMedCrossRef
Govaert KM, Emmink BL, Nijkamp MW, Cheung ZJ, Steller EJ, Fatrai S, de Bruijn MT, Kranenburg O, Rinkes IHB (2014) Hypoxia after liver surgery imposes an aggressive cancer stem cell phenotype on residual tumor cells. Ann Surg 259(4):750–759PubMedCrossRef
Greenhough A, Smartt HJ, Moore AE, Roberts HR, Williams AC, Paraskeva C, Kaidi A (2009) The COX-2/PGE 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30(3):377–386CrossRefPubMed
Hashimoto K, Aoyagi K, Isobe T, Kouhuji K, Shirouzu K (2014) Expression of CD133 in the cytoplasm is associated with cancer progression and poor prognosis in gastric cancer. Gastric Cancer 17(1):97–106PubMedCrossRef
Hatfield SM, Kjaergaard J, Lukashev D, Schreiber TH, Belikoff B, Abbott R, Sethumadhavan S, Philbrook P, Ko K, Cannici R (2015) Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci Transl Med 7(277):277ra230CrossRef
Haynes J, McKee TD, Haller A, Wang Y, Leung C, Gendoo DM, Lima-Fernandes E, Kreso A, Wolman R, Szentgyorgyi E (2018) Administration of hypoxia-activated prodrug evofosfamide after conventional adjuvant therapy enhances therapeutic outcome and targets cancer-initiating cells in preclinical models of colorectal cancer. Clin Cancer Res 24(9):2116–2127PubMedCrossRef
Holodny AI, Schulder M, Liu W-C, Wolko J, Maldjian JA, Kalnin AJ (2000) The effect of brain tumors on BOLD functional MR imaging activation in the adjacent motor cortex: implications for image-guided neurosurgery. Am J Neuroradiol 21(8):1415–1422PubMedPubMedCentral
Hou P-C, Li Y-H, Lin S-C, Lin S-C, Lee J-C, Lin B-W, Liou J-P, Chang J-Y, Kuo C-C, Liu Y-M (2017) Hypoxia-induced downregulation of DUSP-2 phosphatase drives colon cancer stemness. Cancer Res 77(16):4305–4316PubMedCrossRef
Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S (2010) Cancer stem cells in glioblastoma—molecular signaling and therapeutic targeting. Protein Cell 1(7):638–655PubMedPubMedCentralCrossRef
Iwadate Y, Matsutani T, Hirono S, Shinozaki N, Saeki N (2016) Transforming growth factor-β and stem cell markers are highly expressed around necrotic areas in glioblastoma. J Neurooncol 129(1):101–107PubMedCrossRef
Iyer AK, Singh A, Ganta S, Amiji MM (2013) Role of integrated cancer nanomedicine in overcoming drug resistance. Adv Drug Deliv Rev 65(13–14):1784–1802PubMedCrossRef
Jacobsson H, Harrison H, Hughes É, Persson E, Rhost S, Fitzpatrick P, Gustafsson A, Andersson D, Gregersson P, Magnusson Y (2019) Hypoxia-induced secretion stimulates breast cancer stem cell regulatory signalling pathways. Mol Oncol 13(8):1693–1705PubMedPubMedCentralCrossRef
Jeong H, Kim S, Hong B-J, Lee C-J, Kim Y-E, Bok S, Oh J-M, Gwak S-H, Yoo MY, Lee MS (2019) Tumor-associated macrophages enhance tumor hypoxia and aerobic glycolysis. Cancer Res 79(4):795–806PubMed
Jing L, Ruan Z, Sun H, Li Q, Han L, Huang L, Yu S, Wang Y, Guo H, Jiao M (2019) Epithelial–mesenchymal transition induced cancer-stem-cell-like characteristics in hepatocellular carcinoma. J Cell Physiol 234(10):18448–18458PubMedCrossRef
Johnson RW, Finger EC, Olcina MM, Vilalta M, Aguilera T, Miao Y, Merkel AR, Johnson JR, Sterling JA, Wu JY (2016) Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the bone marrow. Nat Cell Biol 18(10):1078PubMedPubMedCentralCrossRef
Kahlert U, Mooney S, Natsumeda M, Steiger HJ, Maciaczyk J (2017) Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways. Int J Cancer 140(1):10–22PubMedCrossRef
Kaneko S, Sato C, Shiozawa N, Sato A, Sato H, Virgona N, Yano T (2018) Suppressive effect of delta-tocotrienol on hypoxia adaptation of prostate cancer stem-like cells. Anticancer Res 38(3):1391–1399PubMed
Kang S-H, Cho HT, Devi S, Zhang Z, Escuin D, Liang Z, Mao H, Brat DJ, Olson JJ, Simons JW (2006) Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res 66(24):11991–11997PubMedCrossRef
Kao S-H, Cheng W-C, Wang Y-T, Wu H-T, Yeh H-Y, Chen Y-J, Tsai M-H, Wu K-J (2019) Regulation of miRNA biogenesis and histone modification by K63-polyubiquitinated DDX17 controls cancer stem-like features. Cancer Res 2376:2018
Kim H, Lin Q, Glazer PM, Yun Z (2018) The hypoxic tumor microenvironment in vivo selects the cancer stem cell fate of breast cancer cells. Breast Cancer Res 20(1):16PubMedPubMedCentralCrossRef
Lee K-M, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, Nixon MJ, Estrada MV, Sánchez V, Sanders ME (2017) MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab 26(4):633–647PubMedPubMedCentralCrossRef
Lee J, Kim CK, Gu K-w, Park W (2019) Value of blood oxygenation level-dependent MRI for predicting clinical outcomes in uterine cervical cancer treated with concurrent chemoradiotherapy. Eur Radiol 29(11):6256–6265PubMedCrossRef
Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE (2009) Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15(6):501–513PubMedPubMedCentralCrossRef
Li H, Xu F, Li S, Zhong A, Meng X, Lai M (2016) The tumor microenvironment: an irreplaceable element of tumor budding and epithelial-mesenchymal transition-mediated cancer metastasis. Cell Adhes Migr 10(4):1–13CrossRef
Li B, Li C, Zhu M, Zhang Y, Du J, Xu Y, Liu B, Gao F, Liu H, Cai J (2017) Hypoxia-induced mesenchymal stromal cells exhibit an enhanced therapeutic effect on radiation-induced lung injury in mice due to an increased proliferation potential and enhanced antioxidant ability. Cell Physiol Biochem 44(4):1295–1310PubMedCrossRef
Li H, Yan W, Suo X, Peng H, Yang X, Li Z, Zhang J, Liu D (2019) Nucleus-targeted nano delivery system eradicates cancer stem cells by combined thermotherapy and hypoxia-activated chemotherapy. Biomaterials 200:1–14PubMedCrossRef
Liang J, Cheng Q, Huang J, Ma M, Zhang D, Lei X, Xiao Z, Zhang D, Shi C, Luo L (2019) Monitoring tumour microenvironment changes during anti-angiogenesis therapy using functional MRI. Angiogenesis 22(3):457–470PubMedCrossRef
Lin C-M, Yu C-F, Huang H-Y, Chen F-H, Hong J-H, Chiang C-S (2019) Distinct tumor microenvironment at tumor edge as a result of astrocyte activation is associated with therapeutic resistance for brain tumor. Front Oncol 9:307PubMedPubMedCentralCrossRef
Liu L, Salnikov AV, Bauer N, Aleksandrowicz E, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Schemmer P, Werner J (2014) Triptolide reverses hypoxia-induced epithelial–mesenchymal transition and stem-like features in pancreatic cancer by NF-κB downregulation. Int J Cancer 134(10):2489–2503PubMedCrossRef
Liu Y, Chen C, Qian P, Lu X, Sun B, Zhang X, Wang L, Gao X, Li H, Chen Z (2015) Gd-metallofullerenol nanomaterial as non-toxic breast cancer stem cell-specific inhibitor. Nat Commun 6:5988PubMedCrossRef
Lloyd MC, Cunningham JJ, Bui MM, Gillies RJ, Brown JS, Gatenby RA (2016) Darwinian dynamics of intratumoral heterogeneity: not solely random mutations but also variable environmental selection forces. Cancer Res 76(11):3136–3144PubMedPubMedCentralCrossRef
Louie E, Nik S, Chen J-s, Schmidt M, Song B, Pacson C, Chen XF, Park S, Ju J, Chen EI (2010) Identification of a stem-like cell population by exposing metastatic breast cancer cell lines to repetitive cycles of hypoxia and reoxygenation. Breast Cancer Res 12(6):R94PubMedPubMedCentralCrossRef
Lu H, Samanta D, Xiang L, Zhang H, Hu H, Chen I, Bullen JW, Semenza GL (2015) Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype. Proc Natl Acad Sci 112(33):E4600–E4609PubMedCrossRefPubMedCentral
Maciaczyk D, Picard D, Zhao L, Koch K, Herrera-Rios D, Li G, Marquardt V, Pauck D, Hoerbelt T, Zhang W (2017) CBF1 is clinically prognostic and serves as a target to block cellular invasion and chemoresistance of EMT-like glioblastoma cells. Br J Cancer 117(1):102PubMedPubMedCentralCrossRef
Man J, Yu X, Huang H, Zhou W, Xiang C, Huang H, Miele L, Liu Z, Bebek G, Bao S (2018) Hypoxic induction of vasorin regulates Notch1 turnover to maintain glioma stem-like cells. Cell Stem Cell 22(1):104–118PubMedCrossRef
Marhold M, Tomasich E, El-Gazzar A, Heller G, Spittler A, Horvat R, Krainer M, Horak P (2015) HIF1α regulates mTOR signaling and viability of prostate cancer stem cells. Mol Cancer Res 13(3):556–564PubMedCrossRef
Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY (2013) Nanomedicine therapeutic approaches to overcome cancer drug resistance. Adv Drug Deliv Rev 65(13–14):1866–1879PubMedPubMedCentralCrossRef
McDonald PC, Chafe SC, Dedhar S (2016) Overcoming hypoxia-mediated tumor progression: combinatorial approaches targeting pH regulation, angiogenesis and immune dysfunction. Front Cell Dev Biol 4:27PubMedPubMedCentralCrossRef
McIntyre A, Hulikova A, Ledaki I, Snell C, Singleton D, Steers G, Seden P, Jones D, Bridges E, Wigfield S (2016) Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth. Cancer Res 76(13):3744–3755PubMedCrossRef
Melzer C, von der Ohe J, Lehnert H, Ungefroren H, Hass R (2017) Cancer stem cell niche models and contribution by mesenchymal stroma/stem cells. Mol Cancer 16(1):28PubMedPubMedCentralCrossRef
Minata M, Audia A, Shi J, Lu S, Bernstock J, Pavlyukov MS, Das A, Kim S-H, Shin YJ, Lee Y (2019) Phenotypic plasticity of invasive edge glioma stem-like cells in response to ionizing radiation. Cell Rep 26(7):1893–1905PubMedPubMedCentralCrossRef
Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A (2010) Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 7(2):150–161PubMedCrossRef
Mondal S, Bhattacharya K, Mandal C (2018) Nutritional stress reprograms dedifferentiation in glioblastoma multiforme driven by PTEN/Wnt/Hedgehog axis: a stochastic model of cancer stem cells. Cell Death Discov 4(1):110PubMedPubMedCentralCrossRef
Muramatsu S, Tanaka S, Mogushi K, Adikrisna R, Aihara A, Ban D, Ochiai T, Irie T, Kudo A, Nakamura N (2013) Visualization of stem cell features in human hepatocellular carcinoma reveals in vivo significance of tumor-host interaction and clinical course. Hepatology 58(1):218–228PubMedCrossRef
Najafi M, Mortezaee K, Majidpoor J (2019a) Cancer stem cell (CSC) resistance drivers. Life Sciences 234:116781PubMedCrossRef
Najafi M, Farhood B, Mortezaee K (2019b) Cancer stem cells (CSCs) in cancer progression and therapy. J Cell Physiol 234(6):8381–8395PubMedCrossRef
Nantajit D, Lin D, Li JJ (2015) The network of epithelial–mesenchymal transition: potential new targets for tumor resistance. J Cancer Res Clin Oncol 141(10):1697–1713PubMedCrossRef
Ogawa S, Lee T-M, Kay AR, Tank DW (1990) Brain magnetic resonance imaging with contrast dependent on blood oxygenation. Proc Natl Acad Sci 87(24):9868–9872PubMedCrossRefPubMedCentral
Pani G, Galeotti T, Chiarugi P (2010) Metastasis: cancer cell’s escape from oxidative stress. Cancer Metastasis Rev 29(2):351–378PubMedCrossRef
Pietras A, Katz AM, Ekström EJ, Wee B, Halliday JJ, Pitter KL, Werbeck JL, Amankulor NM, Huse JT, Holland EC (2014) Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth. Cell Stem Cell 14(3):357–369PubMedPubMedCentralCrossRef
Pires IM, Bencokova Z, Milani M, Folkes LK, Li J-L, Stratford MR, Harris AL, Hammond EM (2010) Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. Cancer Res 70(3):925–935PubMedPubMedCentralCrossRef
Pistollato F, Giampieri F, Battino M (2015) The use of plant-derived bioactive compounds to target cancer stem cells and modulate tumor microenvironment. Food Chem Toxicol 75:58–70PubMedCrossRef
Plaks V, Kong N, Werb Z (2015) The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 16(3):225–238PubMedPubMedCentralCrossRef
Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9(4):265PubMedCrossRef
Qiang L, Wu T, Zhang H, Lu N, Hu R, Wang Y, Zhao L, Chen F, Wang X, You Q (2012) HIF-1α is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death Differ 19(2):284PubMedCrossRef
Qin J, Liu Y, Lu Y, Liu M, Li M, Li J, Wu L (2017) Hypoxia-inducible factor 1 alpha promotes cancer stem cells-like properties in human ovarian cancer cells by upregulating SIRT1 expression. Sci Rep 7(1):10592PubMedPubMedCentralCrossRef
Rapisarda A, Melillo G (2012) Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 9(7):378PubMedCrossRef
Sabelström H, Quigley DA, Fenster T, Foster DJ, Fuchshuber CA, Saxena S, Yuan E, Li N, Paterno F, Phillips JJ (2019) High density is a property of slow-cycling and treatment-resistant human glioblastoma cells. Exp Cell Res 378(1):76–86PubMedCrossRef
Samanta D, Gilkes DM, Chaturvedi P, Xiang L, Semenza GL (2014) Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. Proc Natl Acad Sci 111(50):E5429–E5438PubMedCrossRefPubMedCentral
Schito L, Semenza GL (2016) Hypoxia-inducible factors: master regulators of cancer progression. Trends Cancer 2(12):758–770PubMedCrossRef
Schonberg DL, Lubelski D, Miller TE, Rich JN (2014) Brain tumor stem cells: molecular characteristics and their impact on therapy. Mol Asp Med 39:82–101CrossRef
Schwab LP, Peacock DL, Majumdar D, Ingels JF, Jensen LC, Smith KD, Cushing RC, Seagroves TN (2012) Hypoxia-inducible factor 1α promotes primary tumor growth and tumor-initiating cell activity in breast cancer. Breast Cancer Res 14(1):R6PubMedPubMedCentralCrossRef
Semenza GL (2016a) The hypoxic tumor microenvironment: a driving force for breast cancer progression. Biochimica et Biophysica Acta (BBA)-Mol Cell Res 1863(3):382–391CrossRef
Semenza GL (2016b) Dynamic regulation of stem cell specification and maintenance by hypoxia-inducible factors. Mol Asp Med 47:15–23CrossRef
Shiraishi A, Tachi K, Essid N, Tsuboi I, Nagano M, Kato T, Yamashita T, Bando H, Hara H, Ohneda O (2017) Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells. Cancer Sci 108(3):362–372PubMedPubMedCentralCrossRef
Stadlbauer A, Zimmermann M, Bennani-Baiti B, Helbich TH, Baltzer P, Clauser P, Kapetas P, Bago-Horvath Z, Pinker K (2019) Development of a non-invasive assessment of hypoxia and neovascularization with magnetic resonance imaging in benign and malignant breast tumors: initial Results. Mol Imag Biol 21(4):758–770CrossRef
Storci G, Bertoni S, De Carolis S, Papi A, Nati M, Ceccarelli C, Pirazzini C, Garagnani P, Ferrarini A, Buson G (2013) Slug/β-catenin–dependent proinflammatory phenotype in hypoxic breast cancer stem cells. Am J Pathol 183(5):1688–1697PubMedCrossRef
Sui X, Cai J, Li H, He C, Zhou C, Dong Y, Chen L, Zhang B, Wang Y, Zhang Y (2018) p53-dependent CD51 expression contributes to characteristics of cancer stem cells in prostate cancer. Cell Death Dis 9(5):523PubMedPubMedCentralCrossRef
Sundar SJ, Hsieh JK, Manjila S, Lathia JD, Sloan A (2014) The role of cancer stem cells in glioblastoma. Neurosurg Focus 37(6):E6PubMedCrossRef
Tang Y-A, Chen Y-f, Bao Y, Mahara S, Yatim SMJ, Oguz G, Lee PL, Feng M, Cai Y, Tan EY (2018) Hypoxic tumor microenvironment activates GLI2 via HIF-1α and TGF-β2 to promote chemoresistance in colorectal cancer. Proc Natl Acad Sci 115(26):E5990–E5999PubMedCrossRefPubMedCentral
Vadde R, Vemula S, Jinka R, Merchant N, Bramhachari PV, Nagaraju GP (2017) Role of hypoxia-inducible factors (HIF) in the maintenance of stemness and malignancy of colorectal cancer. Crit Rev Oncol/Hematol 113:22–27CrossRef
Van Den Beucken T, Koch E, Chu K, Rupaimoole R, Prickaerts P, Adriaens M, Voncken JW, Harris AL, Buffa FM, Haider S (2014) Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun 5:5203PubMedCrossRef
Varna M, Gapihan G, Feugeas J-P, Ratajczak P, Tan S, Ferreira I, Leboeuf C, Setterblad N, Duval A, Verine J (2015) Stem cells increase in numbers in perinecrotic areas in human renal cancer. Clin Cancer Res 21(4):916–924PubMedCrossRef
Vaupel P, Mayer A, Höckel M (2004) Tumor hypoxia and malignant progression. Methods Enzymol 381:335–354PubMedCrossRef
Vermeulen L, Felipe De Sousa EM, Van Der Heijden M, Cameron K, De Jong JH, Borovski T, Tuynman JB, Todaro M, Merz C, Rodermond H (2010) Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12(5):468PubMedCrossRef
Wang P, Wan W, Xiong S, Wang J, Zou D, Lan C, Yu S, Liao B, Feng H, Wu N (2017a) HIF1α regulates glioma chemosensitivity through the transformation between differentiation and dedifferentiation in various oxygen levels. Sci Rep 7(1):7965PubMedPubMedCentralCrossRef
Wang P, Wan W-w, Xiong S-L, Feng H, Wu N (2017b) Cancer stem-like cells can be induced through dedifferentiation under hypoxic conditions in glioma, hepatoma and lung cancer. Cell Death Discov 3:16105PubMedPubMedCentralCrossRef
Wei J, Wu A, Kong L-Y, Wang Y, Fuller G, Fokt I, Melillo G, Priebe W, Heimberger AB (2011) Hypoxia potentiates glioma-mediated immunosuppression. PloS One 6(1):e16195PubMedPubMedCentralCrossRef
Won C, Kim BH, Yi EH, Choi KJ, Kim EK, Jeong JM, Lee JH, Jang JJ, Yoon JH, Jeong WI (2015) Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma. Hepatology 62(4):1160–1173PubMedCrossRef
Wu S-L, Li Y-J, Liao K, Shi L, Zhang N, Liu S, Hu Y-Y, Li S-L, Wang Y (2017) 2-Methoxyestradiol inhibits the proliferation and migration and reduces the radioresistance of nasopharyngeal carcinoma CNE-2 stem cells via NF-κB/HIF-1 signaling pathway inactivation and EMT reversal. Oncol Rep 37(2):793–802PubMedCrossRef
Xing F, Okuda H, Watabe M, Kobayashi A, Pai SK, Liu W, Pandey PR, Fukuda K, Hirota S, Sugai T (2011) Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene 30(39):4075PubMedPubMedCentralCrossRef
Yan Y, Liu F, Han L, Zhao L, Chen J, Olopade OI, He M, Wei M (2018a) HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. J Exp Clin Cancer Res 37(1):256PubMedPubMedCentralCrossRef
Yan B, Jiang Z, Cheng L, Chen K, Zhou C, Sun L, Qian W, Li J, Cao J, Xu Q (2018b) Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. Exp Cell Res 371(1):63–71PubMedCrossRef
Yang L, Lin C, Wang L, Guo H, Wang X (2012) Hypoxia and hypoxia-inducible factors in glioblastoma multiforme progression and therapeutic implications. Exp Cell Res 318(19):2417–2426PubMedCrossRef
Zhang X, de Milito A, Olofsson M, Gullbo J, D’Arcy P, Linder S (2015) Targeting mitochondrial function to treat quiescent tumor cells in solid tumors. Int J Mol Sci 16(11):27313–27326PubMedPubMedCentralCrossRef
Zhang F, Duan S, Tsai Y, Keng PC, Chen Y, Lee SO, Chen Y (2016) Cisplatin treatment increases stemness through upregulation of hypoxia-inducible factors by interleukin-6 in non-small cell lung cancer. Cancer Sci 107(6):746–754PubMedPubMedCentralCrossRef
Zhang Q, Lou Y, Zhang J, Fu Q, Wei T, Sun X, Chen Q, Yang J, Bai X, Liang T (2017) Hypoxia-inducible factor-2α promotes tumor progression and has crosstalk with Wnt/β-catenin signaling in pancreatic cancer. Mol Cancer 16(1):119PubMedPubMedCentralCrossRef
Zhang Z, Han H, Rong Y, Zhu K, Zhu Z, Tang Z, Xiong C, Tao J (2018) Hypoxia potentiates gemcitabine-induced stemness in pancreatic cancer cells through AKT/Notch1 signaling. J Exp Clin Cancer Res 37(1):291PubMedPubMedCentralCrossRef
Zhu H, Wang D, Liu Y, Su Z, Zhang L, Chen F, Zhou Y, Wu Y, Yu M, Zhang Z (2013) Role of the Hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133 + pancreatic cancer stem-like cells. Cancer Cell Int 13(1):119PubMedPubMedCentralCrossRef
Metadata
Title
Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance
Authors
Masoud Najafi
Bagher Farhood
Keywan Mortezaee
Ebrahim Kharazinejad
Jamal Majidpoor
Reza Ahadi
Publication date
01-01-2020
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 1/2020
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-019-03080-1

Other articles of this Issue 1/2020

Journal of Cancer Research and Clinical Oncology 1/2020 Go to the issue

Original Article – Clinical Oncology

Safety and efficacy of CT-guided radioactive iodine-125 seed implantation assisted by a 3D printing template for the treatment of thoracic malignancies

Original Article – Clinical Oncology

The age-adjusted Charlson comorbidity index as a predictor of overall survival of surgically treated non-metastatic clear cell renal cell carcinoma

Review – Clinical Oncology

Evolving the pulmonary nodules diagnosis from classical approaches to deep learning-aided decision support: three decades’ development course and future prospect

Original Article – Clinical Oncology

Effects of single-nucleotide polymorphisms in the mTORC1 pathway on the risk of brain metastasis in patients with non-small cell lung cancer

Review – Cancer Research

Herbal nutraceuticals: safe and potent therapeutics to battle tumor hypoxia

Original Article – Clinical Oncology

Comparison of survival and renal function between partial and radical laparoscopic nephrectomy for T1b renal cell carcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits